A randomized, double-blind, placebo-controlled phase 3 multicenter study of immediate postoperative instillation of gemcitabine in patients with superficial transitional cell carcinoma of the bladder.

Trial Profile

A randomized, double-blind, placebo-controlled phase 3 multicenter study of immediate postoperative instillation of gemcitabine in patients with superficial transitional cell carcinoma of the bladder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 03 Nov 2009 Actual number of patients changed from 328 to 355.
    • 03 Nov 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Results published in European Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top